Identification of the metabolites of myricitrin produced by human intestinal bacteria in vitro using ultra-performance liquid chromatography/ quadrupole time-of-flight mass spectrometry

Expert Opinion on Drug Metabolism and Toxicology

Volumn 10, Issue 7, 2014, Pages 921-931

  Du, Le Yue ^a   Zhao, Min ^a   Xu, Jun ^a   Qian, Da Wei ^a   Jiang, Shu ^a   Shang, Er Xin ^a   Guo, Jian Ming ^a   Liu, Pei ^a   Su, Shu Lan ^a   Duan, Jin Ao ^a   Leng, Xue Jiao ^a  

^a NANJING UNIVERSITY OF CHINESE MEDICINE   (China)

Author keywords

Human intestinal microbiota; Metabolites; Myricitrin; UPLC Q TOF MS

Indexed keywords

AGLYCONE; HEBACEOUS AGENT; MYRICETIN; MYRICETIN 3 RHAMNOSIDE; QUERCITRIN; RNA 16S; UNCLASSIFIED DRUG; FLAVONOID; MYRICITRIN; QUERCETIN;

ARTICLE; BACTERIUM COLONY; BACTERIUM ISOLATE; DEGLYCOSYLATION; DRUG METABOLISM; ESCHERICHIA COLI; GENE SEQUENCE; HUMAN; IN VITRO STUDY; IN VIVO STUDY; INTESTINE FLORA; MEDICINAL PLANT; METABOLIC CAPACITY; METABOLISM; NONHUMAN; TIME OF FLIGHT MASS SPECTROMETRY; ULTRA PERFORMANCE LIQUID CHROMATOGRAPHY; ADULT; ANALOGS AND DERIVATIVES; FECES; FEMALE; GENETICS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; INTESTINE; MASS SPECTROMETRY; MICROBIOLOGY; PROCEDURES;

ADULT; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; FECES; FEMALE; FLAVONOIDS; HUMANS; IN VITRO TECHNIQUES; INTESTINES; MASS SPECTROMETRY; QUERCETIN; RNA, RIBOSOMAL, 16S;

EID: 84902519491     PISSN: 17425255     EISSN: 17447607     Source Type: Journal    
DOI: 10.1517/17425255.2014.918954     Document Type: Article

References (34)

1. Chen W, Zhuang J, Li Y, et al. Myricitrin protects against peroxynitritemediated DNA damage and cytotoxicity in astrocytes. Food Chem 2013;141:927-33
2. Sun GB, Qin M, Ye JX, et al. Inhibitory effects of myricitrin on oxidative stress-induced endothelialdamage and early atherosclerosis in ApoE/mice. Toxicol Appl Pharmacol 2013;271:114-26
3. Pereira M, Siba IP, Chioca LR, et al. Myricitrin, a nitric oxide and protein kinase C inhibitor, exerts antipsychotic-like effects in animal models. Prog Neuropsychopharmacol Biol Psychiatry 2011;35:1636-44
4. Kim HH, Kim DH, Kim MH, et al. Flavonoid constituents in the leaves of Myrica rubra sieb. et zucc. with antiinflammatory activity. Arch Pharm Res 2013;36:1533-40
5. Yoshimura M, Yamakami S, Amakura Y, et al. Diarylheptanoid sulfates and related compounds from Myrica rubra bark. J Nat Prod 2012;75:1798-802
6. Schutte ME, van de Sandt JJ, Alink GM, et al. Myricetin stimulates the absorption of the pro-carcinogen PhIP. Cancer Lett 2006;231:36-42
7. Meotti FC, Luiz AP, Pizzolatti MG, et al. Analysis of the antinociceptive effect of the flavonoid myricitrin: evidence for a role of the L-Arginine-nitric oxide and protein kinase C pathways. J Pharmacol Exp Ther 2006;316:789-96
8. Chen W, Feng L, Shen Y, et al. Myricitrin inhibits acrylamide-mediated cytotoxicity in human Caco-2 cells by preventing oxidative stress. Biomed Res Int 2013;2013:724183
9. Eckburg PB, Bik EM, Bernstein CN, et al. Diversity of the human intestinal microbial flora. Science 2005;308:1635-8
10. Proctor LM. The human microbiome project in 2011 and beyond. Cell Host Microbe 2011;10:287-91
11. Blaut M, Braune A, Wunderlich S, et al. Mutagenicity of arbutin in mammalian cells after activation by human intestinal bacteria. Food Chem Toxicol 2006;44:1940-7
12. Sousa T, Paterson R, Moore V, et al. The gastrointestinal microbiota as a site for the biotransformation of drugs. Int J Pharm 2008;363:1-25
13. Kang MJ, Kim HG, Kim JS, et al. The effect of gut microbiota on drug metabolism. Expert Opin Drug Metab Toxicol 2013;9:1295-308
14. Shen H, Leung WI, Ruan JQ, et al. Biotransformation of ginsenoside Rb1 via the gypenoside pathway by human gut bacteria. Chin Med 2013;8(1):22
15. Ye R, Kong X, Yang Q, et al. Ginsenoside Rd attenuates redox imbalance and improves stroke outcome after focal cerebral ischemia in aged mice. Neuropharmacology 2011;61:815-24
16. Shen J, Yang C, Wu C, et al. Identification of the major metabolites of quinocetone in swine urine using ultra-performance liquid chromatography/ electrospray ionization quadrupole time-of-flight tandem mass spectrometry. Rapid Commun Mass Spectrom 2010;24:375-83
17. Han H, Yang L, Xu Y, et al. Identification of metabolites of geniposide in rat urine using ultraperformance liquid chromatography combined with electrospray ionization quadrupole time-of-flight tandem mass spectrometry. Rapid Commun Mass Spectrom 2011;25:3339-50
18. Hur HG, Lay JO Jr, Beger RD, et al. Isolation of human intestinal bacteria metabolizing the natural isoflavone glycosides daidzin and genistin. Arch Microbiol 2000;174:422-8
19. Minamida K, Tanaka M, Abe A, et al. Production of equol from daidzein by gram-positive rod-shaped bacterium isolated from rat intestine. J Biosci Bioeng 2006;102:247-50
20. Iqbal M, Alam A, Wani TA, et al. Simultaneous determination of reserpine, rescinnamine, and yohimbine in human plasma by ultraperformance liquid chromatography tandem mass spectrometry. J Anal Methods Chem 2013;2013:940861
21. Ishii S, Sadowsky MJ. Escherichia coli in the environment: implications for water quality and human health. Microbes Environ 2008;23:101-8
22. Nirmala P, Ramanathan M. Effect of myricetin on 1, 2 dimethylhydrazine induced rat colon carcinogenesis. J Exp Ther Oncol 2011;9:101-8
23. DeToma AS, Choi JS, Braymer JJ, et al. Myricetin: A naturally occurring regulator of metal-induced amyloid-beta aggregation and neurotoxicity. Chembiochem 2011;12:1198-201
24. Liu IM, Liou SS, Lan TW, et al. Myricetin as the active principle of Abelmoschus moschatus to lower plasma glucose in streptozotocin-induced diabetic rats. Planta Med 2005;71:617-21
25. Jung SK, Lee KW, Kim HY, et al. Myricetin suppresses UVB-induced wrinkle formation and MMP-9 expression by inhibiting Raf. Biochem Pharmacol 2010;79:1455-61
26. Shin JC, Jung HY, Harikishore A, et al. The flavonoid myricetin reduces nocturnal melatonin levels in the blood through the inhibition of serotonin N-Acetyltransferase. Biochem Biophys Res Commun 2013;440:312-16
27. Yokomizo A, Moriwaki M. Myricitrin degraded by simulated digestion inhibits oxidation of human low-density lipoprotein. Biosci Biotechnol Biochem 2005;69:693-9
28. Ma X, Tian W, Wu L, et al. Isolation of quercetin-3-O-L-rhamnoside from Acer truncatum Bunge by high-speed counter-current chromatography. J Chromatogr A 2005;1070:211-14
29. Boots AW, Haenen GR, Bast A. Health effects of quercetin: from antioxidant to nutraceutical. Eur J Pharmacol 2008;585:325-37
30. Kleemann R, Verschuren L, Morrison M, et al. Anti-inflammatory, anti-proliferative and anti-Atherosclerotic effects of quercetin in human in vitro and in vivo models. Atherosclerosis 2011;218:44-52
31. Dajas F. Life or death: neuroprotective and anticancer effects of quercetin. J Ethnopharmacol 2012;143:383-96
32. Masimirembwa CM, Bredberg U, Andersson TB. Metabolic stability for drug discovery and development: pharmacokinetic and biochemical challenges. Clin Pharmacokinet 2003;42:515-28
33. Gomez-Lechon MJ, Castell JV, Donatoa MT. Hepatocytes-The choice to investigate drug metabolism and toxicity in man: in vitro variability as a reflection of in vivo. Chem Biol Interact 2007;168:30-50
34. Graefe EU, Wittig J, Mueller S, et al. Pharmacokinetics and bioavailability of quercetin glycosides in humans. J Clin Pharmacol 2001;41:492-9